Serum thyroglobulin testing using SISCAPA® technology and liquid chromatography, tandem mass spectrometry now performed at Mayo Medical Laboratories
Serum Tg measurements are central to monitoring treated thyroid cancer patients for persistent or recurrent disease. For decades, Tg measurements have relied on methods that are subject to interference by anti-Tg autoantibodies, which might be found in 20-30% of thyroid cancer patients. As a result, many patients are being subjected to additional imaging studies that might be avoided by utilizing more specific laboratory testing methods, such as SISCAPA-MS.
“By adding this test, we are now able to provide more meaningful test results in cases of thyroglobulin autoantibody interference where the physicians were unsure about the disease status of the patient,” says Stefan K. Grebe, M.D., Ph.D., Chair of Clinical Biochemistry and Immunology at Mayo Clinic.
SISCAPA-MS measures unique peptides to avoid autoantibody interferences, and incorporates internal standards to correct for many sample processing and assay problems. It was developed to provide a flexible multiplex assay-development platform for creation of assays to verify clinical utility of candidate protein biomarkers in large sample sets. As a licensee of SISCAPA technology, Mayo has developed a robust and sensitive laboratory test for the thyroid cancer tumor marker Tg.
“We are proud to have Mayo as a licensee,” said Selena Larkin, Vice President of Marketing and Sales at SISCAPA Assay Technologies (SAT), “and we congratulate them on the development of this new test for cancer recurrence. This represents the latest example of our clients realizing SAT’s vision for the importance of improved clinical tests.”
To learn more about thyroglogulin testing using SISCAPA technology, and how to order the test, please visit MayoMedical Laboratories.com and view the Thyroglobulin Mass Spectrometry, Serum test information.
About Mayo Medical Laboratories/Department of Laboratory Medicine and Pathology The Department of Laboratory Medicine and Pathology at Mayo Clinic maintains an active diagnostic test development program. These activities also incorporate technologies from collaborations with diagnostic and biotechnology companies. Mayo utilizes these proven diagnostic technologies in the care of its patients and offers them to more than 5,000 health care institutions around the world through Mayo Medical Laboratories. Revenue from this testing is used to support medical education and research at Mayo Clinic.
About SISCAPA Assay Technologies, Inc. SISCAPA Assay Technologies Inc. (SAT) delivers tools for development of high-sensitivity, high-throughput specific assays for proteins, including clinical biomarkers, using SISCAPA® (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) technology. SISCAPA is a registered trademark of SISCAPA Assay Technologies Inc. in the United States and/or other countries. Additional information about SISCAPA technology, reagents and licensing is available at http://www.SISCAPA.com.